Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity
Emanuela Teveroni, … , Giancarlo Deidda, Fabiola Moretti
Emanuela Teveroni, … , Giancarlo Deidda, Fabiola Moretti
Published March 6, 2017
Citation Information: J Clin Invest. 2017;127(4):1531-1545. https://doi.org/10.1172/JCI89401.
View: Text | PDF
Research Article Endocrinology Muscle biology

Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity

  • Text
  • PDF
Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder that is characterized by extreme variability in symptoms, with females being less severely affected than males and presenting a higher proportion of asymptomatic carriers. The sex-related factors involved in the disease are not known. Here, we have utilized myoblasts isolated from FSHD patients (FSHD myoblasts) to investigate the effect of estrogens on muscle properties. Our results demonstrated that estrogens counteract the differentiation impairment of FSHD myoblasts without affecting cell proliferation or survival. Estrogen effects are mediated by estrogen receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity of double homeobox 4 (DUX4), a protein whose aberrant expression has been implicated in FSHD pathogenesis. During myoblast differentiation, we observed that the levels and activity of DUX4 increased progressively and were associated with its enhanced recruitment in the nucleus. ERβ interfered with this recruitment by relocalizing DUX4 in the cytoplasm. This work identifies estrogens as a potential disease modifier that underlie sex-related differences in FSHD by protecting against myoblast differentiation impairments in this disease.

Authors

Emanuela Teveroni, Marsha Pellegrino, Sabrina Sacconi, Patrizia Calandra, Isabella Cascino, Stefano Farioli-Vecchioli, Angela Puma, Matteo Garibaldi, Roberta Morosetti, Giorgio Tasca, Enzo Ricci, Carlo Pietro Trevisan, Giuliana Galluzzi, Alfredo Pontecorvi, Marco Crescenzi, Giancarlo Deidda, Fabiola Moretti

×

Figure 1

E2 enhances differentiation of immortalized FSHD myoblasts.

Options: View larger image (or click on image) Download as PowerPoint
E2 enhances differentiation of immortalized FSHD myoblasts.
(A–L) Repres...
(A–L) Representative photographs of MHC immunostaining (red) of myoblasts from indicated FSHD patients and healthy individuals after 7 days of culture in differentiation medium in the absence or presence of 10−8 M E2. Nuclei were counterstained with DAPI (blue). Scale bar: 75 μm. (M) Percentage of MHC+ cells treated as in A–L. Percentage MHC+ cells = MHC+ nuclei/total number of nuclei. Pink bars represent female, blue bars male myoblasts. (N) Fusion index in the same fields analyzed in M. Fusion index = percentage of nuclei in MHC + myotube/number of total nuclei, where a myotube is a MHC+ cell with 3 nuclei. Data in M and N represent the mean ± SD of 3 independent experiments, except 2 experiments are represented for FSHD#2 and CTLs. For each experiment, 4 fields/condition were counted (n = 12 for FSHD#1, FSHD#3, and FSHD#4; n = 8 for FSHD#2, CTL#1, and CTL#2). ***P < 0.001; **P < 0.01; *P < 0.05, 2-tailed Student’s t test. The complete set of fields evaluated in this experiment is reported in Supplemental Figure 6.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts